Susquehanna International Group, LLP Precision Biosciences Inc Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $170,792 - $447,752	-57,700 Reduced 80.25%	14,200 $44,000
Q4 2021 Feb 14, 2022	SELL	$7.4 - $11.66 $300,440 - $473,396	-40,600 Reduced 36.09%	71,900 $532,000
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $78,030 - $120,275	-8,500 Reduced 7.02%	112,500 $1.3 Million
Q2 2021 Aug 11, 2021	BUY	$8.07 - $12.52 $341,361 - $529,596	42,300 Added 53.75%	121,000 $1.52 Million
Q1 2021 May 17, 2021	BUY	$8.57 - $15.79 $582,760 - $1.07 Million	68,000 Added 635.51%	78,700 $815,000
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $31,096 - $64,844	-5,200 Reduced 32.7%	10,700 $89,000
Q3 2020 Nov 16, 2020	SELL	$4.65 - $8.73 $35,340 - $66,348	-7,600 Reduced 32.34%	15,900 $98,000
Q2 2020 Aug 14, 2020	BUY	$4.66 - $8.7 $14,446 - $26,969	3,100 Added 15.2%	23,500 $196,000
Q1 2020 May 15, 2020	BUY	$5.05 - $15.01 $34,845 - $103,569	6,900 Added 51.11%	20,400 $123,000
Q4 2019 Feb 14, 2020	BUY	$6.32 - $19.66 $85,320 - $265,410	13,500 New	13,500 $188,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $553M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.